🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients

Recruitingn/aAges 18 Years - 75 YearsAllFondazione IRCCS Policlinico San Matteo di Pavia
NCT07563608 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease undergoing chronic hemodialysis. The research seeks to identify specific clinical factors and biomarkers like angiopoietin-2 that contribute to the development of this condition, while evaluating the prognostic value of right ventricular function measured via TAPSE. Participants undergo a standardized screening echocardiogram the day after their intermediate dialysis session to determine the probability of pulmonary hypertension. Those identified as high-risk receive further diagnostic confirmation through right heart catheterization, respiratory function tests, and lung scans to clarify the underlying etiology. The protocol also evaluates the hemodynamic impact of high-flow arteriovenous fistulas and volume ove

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged between 18 and 75 years * Patients on stable extracorporeal hemodialysis for at least 6 months * Dialysis frequency of two or three times per week * Ability to provide written informed consent Exclusion Criteria: * WHO functional class IV * Presence of valvular or congenital heart disease * Acute infections within the month preceding the cardiological evaluation
💊

What it tests

  • Not listed
📍

Where

1 site
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy